OBJECTIVES: Information regarding intravenous and subcutaneous administration costs of multiple myeloma (MM) medications in Finland is scattered. Nevertheless, the need of acquisition and administration costs for health economic evaluations (HEE) of MM treatments is evident as these costs can be high. Furthermore, the first oral proteasome inhibitor (PI) treatment for MM, ixazomib, is available, potentially allowing reductions in the treatment acquisition and administration costs. We estimated the treatment acquisition and drug administration costs of infusion or subcutaneous PI treatments (carfilzomib, bortezomib) for MM in Finland. METHODS: Price tariffs of Finnish hospital districts are used as the basis of invoicing sent to health care service payer. Those prices were collected and analyzed to find costs for the relevant MM treatments. Furthermore, detailed inquiries were sent to all Finnish hospital districts to ensure the face validity of prices included. Two costing perspectives were applied: A] acquisition of treatment (until administered to the patient, i.e. both administration and drug cost included) and B] drug administration alone (administration included, drug costs excluded). RESULTS: